Rhode Island Chronicle

TIM-3-Next Generation Immunotherapy Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies – Roche , Novartis, GlaxoSmithKline

 Breaking News
  • No posts were found

TIM-3-Next Generation Immunotherapy Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies – Roche , Novartis, GlaxoSmithKline

September 13
00:42 2023
TIM-3-Next Generation Immunotherapy  Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - Roche , Novartis, GlaxoSmithKline
DelveInsight Business Research LLP
DelveInsight’s ‘TIM-3-Next Generation Immunotherapy—Competitive Landscape and Market Forecast–2035’ report delivers an in-depth understanding of the TIM-3 as well as the market trends of TIM-3-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

DelveInsight’s ‘TIM-3-Next Generation Immunotherapy—Competitive Landscape and Market Forecast–2035’ report delivers an in-depth understanding of the TIM-3 as well as the market trends of TIM-3-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Highlights of the TIM-3-Next Generation Immunotherapy Market 

  • The Key Companies working in the TIM-3-Next Generation Immunotherapy market include GlaxoSmithKline, Novartis, Bristol-Myers Squibb, Ono Pharmaceuticals BeiGene, Incyte Biosciences/Agenus, Symphogen, Roche, Eli Lilly, Symphogen and many others 

  • The Key Therapies working in the TIM-3-Next Generation Immunotherapy market include Sym023, TSR-022, MBG453, ONO-7807, BMS-986258 and many others 

TIM-3-Next Generation Immunotherapy Overview

Cancer immunotherapy (CI) is rapidly advancing and can now be considered to be the “fifth pillar” of cancer therapy, joining the ranks of surgery, cytotoxic chemotherapy, radiation, and targeted therapy. The CI that has sparked the most interest involves antibodies to inhibitory immune checkpoint molecules. Fighting cancer with immunotherapy has revolutionized treatment for some patients and therapies targeting the immune checkpoint molecules such as CTLA-4 and PD-1 have achieved durable responses in melanoma, renal cancer, Hodgkin’s disease, and lung cancer. However, the success rate of these treatments has been low and a large number of cancers, including colorectal cancer remain largely refractory to CTLA-4 and PD-1 blockade.

TIM-3 is a co-inhibitory receptor that is expressed on IFN-γ-producing T cells, FoxP3+ Treg cells, and innate immune cells (macrophages and dendritic cells) where it has been shown to suppress their responses upon interaction with their ligand(s). TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that in vivo blockade of TIM-3 with other checkpoint inhibitors enhances anti-tumor immunity and suppresses tumor growth in several preclinical tumor models.

 

TIM-3-Next Generation Immunotherapy  Epidemiology Insights

  • The prevalence of TIM-3-Next Generation Immunotherapy increases with age. In 2005-2008 an estimated 33.5% of U.S. adults older than 20 years of age had high LDL-C levels. Of these individuals with elevated LDL-C levels, only 48.1% received treatment, and 33.2% had their LDL-C controlled. The prevalence of LDL-C control seemed to be the lowest amongst individuals who were uninsured, Mexican American, or had income below the poverty level.

Click here to learn more about the TIM-3-Next Generation Immunotherapy Market Landscape

The Report Covers the TIM-3-Next Generation Immunotherapy  Epidemiology Segmented by:

  • TIM-3-Next Generation Immunotherapy  diagnosed cases 

  • Total TIM-3-Next Generation Immunotherapy  incident cases

  • Total TIM-3-Next Generation Immunotherapy  prevalent cases 

  • TIM-3-Next Generation Immunotherapy Treatment cases 

TIM-3-Next Generation Immunotherapy  Market Outlook 

The TIM-3-Next Generation Immunotherapy market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted TIM-3-Next Generation Immunotherapy market trends by analyzing the impact of current TIM-3-Next Generation Immunotherapy therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the TIM-3-Next Generation Immunotherapy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated TIM-3-Next Generation Immunotherapy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the TIM-3-Next Generation Immunotherapy market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Companies Working in the TIM-3-Next Generation Immunotherapy Market

• Novartis

• Bristol-Myers Squibb/ Ono Pharmaceuticals

• BeiGene

• Incyte Biosciences/Agenus

• Symphogen

• Roche

• Eli Lilly

And many others 

 

TIM-3-Next Generation Immunotherapy Therapies Covered and Analyzed in the Report

 

  • Sym023

  • TSR-022

  • MBG453 

And many others 

 Learn more about the Key Companies and Emerging Therapies in the TIM-3-Next Generation Immunotherapy Market

 Table of Contents 

  1. Key Insights 

  2. TIM-3-Next Generation Immunotherapy  Introduction 

  3. Executive Summary of TIM-3-Next Generation Immunotherapy           

  4. Disease Background and Overview

  5. Epidemiology and Patient Population

  6. TIM-3-Next Generation Immunotherapy  Emerging Therapies

  7. TIM-3-Next Generation Immunotherapy  Market Outlook

  8. Market Access and Reimbursement of Therapies

  9. Market Drivers 

  10. Market Barriers 

  11. Appendix

  12. Report Methodology

  13. DelveInsight Capabilities

  14. Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Categories